Ruxolitinib cream + Vehicle

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 32/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Hand Eczema

Conditions

Hand Eczema

Trial Timeline

Jul 31, 2023 → Dec 13, 2024

NCT ID

NCT05906628

About Ruxolitinib cream + Vehicle

Ruxolitinib cream + Vehicle is a phase 2 stage product being developed by Incyte for Hand Eczema. The current trial status is completed. This product is registered under clinical trial identifier NCT05906628. Target conditions include Hand Eczema.

What happened to similar drugs?

1 of 10 similar drugs in Hand Eczema were approved

Approved (1) Terminated (2) Active (7)

🔄Lebrikizumab + PlaceboEli LillyPhase 3

🔄Pimecrolimus Cream 1%NovartisPhase 3

🔄tocilizumab + saline solutionRochePhase 3

🔄dupilumab + PlaceboSanofiPhase 3

✅clobetasol propionateGSK plcApproved

❌Ruxolitinib cream + VehicleIncytePhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (6)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05906628	Phase 2	Completed	Jul 31, 2023	Dec 13, 2024	Hand Eczema
NCT05219864	Phase 3	Withdrawn	Jan 31, 2023	Sep 22, 2024	Hand Eczema
NCT05233410	Phase 3	Withdrawn	Jan 31, 2023	Sep 22, 2024	Chronic Hand Eczema (CHE)
NCT05127421	Phase 2	Completed	Nov 10, 2021	Sep 29, 2023	Atopic Dermatitis
NCT04057573	Phase 3	Completed	Oct 3, 2019	Oct 1, 2021	Non-segmental Vitiligo
NCT04052425	Phase 3	Completed	Sep 20, 2019	Oct 21, 2021	Non-segmental Vitiligo

Competing Products

17 competing products in Hand Eczema

See all competitors

Product	Company	Stage	Hype Score
Lebrikizumab + Placebo	Eli Lilly	Phase 3	44
Methylprednisolone Tablet	Johnson & Johnson	Phase 2/3	34
ABT-981 + Placebo for ABT-981	AbbVie	Phase 2	35
Pimecrolimus Cream 1%	Novartis	Phase 3	40
tocilizumab + saline solution	Roche	Phase 3	40
denosumab + Placebo	Amgen	Phase 2	35
Dupilumab + Placebo	Sanofi	Phase 2	31
dupilumab + Placebo	Sanofi	Phase 3	40
clobetasol propionate	GSK plc	Approved	43
urea 40% cream + fluocinonide 0.05% cream + tazarotene 0.1% cream + bland emollient cream (Udderly smooth® Udder Cream)	Bayer	Phase 2	24
Ruxolitinib cream + Vehicle	Incyte	Phase 3	29
Ruxolitinib	Incyte	Phase 1/2	29
Ruxolitinib cream + Vehicle	Incyte	Phase 3	29
ARQ-252 cream 0.3% + ARQ-252 cream 0.1% + ARQ-252 Vehicle Cream	Arcutis Biotherapeutics	Phase 1/2	26
alitretinoin	Basilea Pharmaceutica	Phase 3	34
alitretinoin	Basilea Pharmaceutica	Phase 3	34
alitretinoin	Basilea Pharmaceutica	Phase 3	34